MR907-2502

<!-- [if !supportLists]-->1.    <!--[endif]-->Willing and able to provide written informed consent.

<!-- [if !supportLists]-->2.    <!--[endif]-->Males or females ≥18 years of age

<!-- [if !supportLists]-->3.    <!--[endif]-->Established diagnosis of CPA according to ESCMID/ERS criteria (2016) which includes all the following, which should be present for ≥3 months:

<!-- [if !supportLists]-->o    <!--[endif]-->one or more clinical symptoms (persistent cough, recurrent haemoptysis, weight loss, malaise, night sweats, fever and dyspnoea)

<!-- [if !supportLists]-->o    <!--[endif]-->slowly progressive or persistent radiological findings (one or more cavities and surrounding fibrosis, infiltrates, consolidation, with or without fungal ball or progressive pleural thickening) on computed tomography (CT) of the thorax

<!-- [if !supportLists]-->o    <!--[endif]-->immunological, microbiological or molecular evidence of Aspergillus infection (growth of Aspergillus in respiratory secretions or serum galactomannan index >0.5 or BALF galactomannan index >1), positive Aspergillus IgG, or positive PCR

<!-- [if !supportLists]-->o    <!--[endif]-->exclusion of active tuberculosis or non-tuberculous mycobacterial pulmonary infection or disorders that will prevent evaluation of outcome over 6 months. Patients on anti- mycobacterial therapy can be enrolled if their mycobacterial infection is stabilised.

<!-- [if !supportLists]-->4.    <!--[endif]-->Subjects must be unable to receive systemic azole antifungal therapy due to any of the following: documented or anticipated resistance, intolerance, contraindication (e.g. due to drug-drug interactions or organ dysfunction), inability to take oral medication, or lack of availability. NOTE: the administration of rezafungin is monotherapy only, and subjects currently on azoles who are able to remain on therapy are not eligible

1.  <!--[endif]-->Subjects with invasive aspergillosis, aspergillus nodules, or simple aspergilloma
2. <!-- [if !supportLists]-->Known or suspected hypersensitivity to rezafungin for Injection or any of its excipients
3. <!-- [if !supportLists]-->Current participation in another interventional treatment trial with an investigational agent. Participation in another interventional treatment trial is permitted during the follow-up period of the study
4. <!-- [if !supportLists]-->Recent use of an investigational medicinal product within 28 days or 5 half-lives of the investigational medicinal product, whichever is greater, to prevent overlapping toxicities when this study’s investigational product is dosed, or presence of an investigational device at the time of screening. In some cases, use of investigational products may be acceptable in consultation with the Sponsor’s Medical Monitor
5. <!-- [if !supportLists]-->Administration of any other echinocandin or intravenous antifungal treatment within 3 months of screening
6. Administration of ≥15mg prednisolone daily (or other equivalent immunosuppressant) for at least 3 weeks within 4 weeks of screening OR a peripheral neutrophil count <0.5x109/L 
7. <!-- [if !supportLists]-->Acute respiratory infections considered inadequately treated in the opinion of the Principal Investigator. Any subjects diagnosed with an acute respiratory infection during the screening period should be re-screened following the required course of appropriate treatment and enrolled when considered adequately treated.
8. <!-- [if !supportLists]-->Subjects with active malignancy who are receiving chemotherapy or radiation therapy
9. <!-- [if !supportLists]-->Subjects on the palliative care pathway
10. <!--[endif]-->Any other condition or laboratory abnormality that, in the opinion of the Investigator, would put the subject at unacceptable risk for participation in the study or may interfere with the assessments included in the study
11. <!-- [if !supportLists]-->A. Meets National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, criteria for ataxia, tremor, motor neuropathy, or sensory neuropathy of Grade 2 or higher
    B.  <!--[endif]-->History of severe ataxia, tremor, or neuropathy or a diagnosis of multiple sclerosis or a movement disorder (including Parkinson’s Disease or Huntington’s Disease
12. Planned or ongoing therapy at Screening with a known severe neurotoxic medication or with a known moderate neurotoxic medication in a patient with ataxia, tremor, motor neuropathy, or sensory neuropathy of CTCAE version 5.0 Grade 1 or higher
13. <!-- [if !supportLists]-->Pregnant or lactating females